Recode Therapeutics
Vision
To power the next wave of genetic medicines through superior delivery.
Approach
ReCode is revolutionizing the way genetic medicines are delivered with its next generation Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform. ReCode’s SORT LNP platform is the foundation for its pipeline of disease-modifying mRNA and gene correction therapeutics and is poised to unlock the promise of precision genetic medicines with the ability to selectively target organs and cells beyond the liver.
Recode Therapeutics is addressing
CEO:
Shehnaaz Suliman, M.D., MBA, M.Phil.
Founders:
Arthur Johnson, Ph.D., Philip Thomas, Ph.D, Daniel Siegwart, Ph.D., and Michael Torres, Ph.D. founded the original ReCode. David Lockhart, Ph.D, Leon Chen, Ph.D and Peter Thompson, M.D. founded TranscripTx, which merged with ReCode in 2020 to create the ReCode that exists today.
First investment:
June 2022